Navigation Links
MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
Date:12/4/2008

GAITHERSBURG, Md., Dec. 4 /PRNewswire/ -- MedImmune today announced that it has initiated a Phase 2 clinical trial in patients with chronic asthma to determine the safety of subcutaneous dosing of a humanized monoclonal antibody (MAb) that targets the interleukin-5 receptor (IL-5R). Preclinical data suggest that inhibiting the IL-5R pathway may lead to a targeted approach for treating patients with asthma, supporting continued study of this antibody.

"Asthma can be a very debilitating disease, and despite current therapies, patients are in need of novel treatment options," said Nestor Molfino, M.D., vice president, clinical development, pulmonary disease. "Some asthmatics may show an increased circulation of eosinophils in blood -- a certain type of white blood cell believed to play a critical role in the severity and disease pathway of asthma; therefore administration of this antibody may increase asthma control."

MEDI-563, which was generated using BioWa's POTELLIGENT(TM) Technology platform, has previously been investigated in a Phase 1 open-label dose-escalating study to evaluate the safety and tolerability of a single intravenous infusion in adults with mild-to-moderate asthma. Data from the completed Phase 1 study demonstrated that the antibody was well-tolerated with biologic activity producing substantial and prolonged depletion of blood eosinophils, thus supporting its continued development. Published literature suggests that reduction of eosinophils in sputum was associated with better asthma control and increases in sputum eosinophilia were associated with exacerbations of asthma. The antibody is also currently being evaluated in a double-blind, placebo-controlled Phase 1 study to evaluate the safety and tolerability and effects of the antibody on airway eosinophils in adults with asthma.

About Interleukin-5 Receptor (IL-5R)

Interleukin-5 is a cytokine secreted predominantly
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. MedImmune Announces Zook as President
2. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
3. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
4. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
5. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
6. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
7. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
8. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
9. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
10. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
11. Seneca Valley High School Student Receives Science Award From MedImmune

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., BOSTON, Nov. 25 Biotech firm Rep...nomic data from the 1918 pandemic through the pred... pandemic, today issued its latest biochemical ana...thality of the H1N1 ("Swine Flu") virus has droppe...,s current outbreak in the spring of 2009 to resti...
(Date:11/25/2009)... , ,, BOCA RATON, Fla., Nov. 25 /P... painful year. Not so for BodyLogicMD. The nation...hysicians specializing exclusively in medically su...mber of physicians in its network since Nove...progress to add more physician-owned centers, incl...
(Date:11/25/2009)..., BEIJING, Nov. 25 /PRNewswire-Asia/ -- Sinov...ovider of vaccines, announced today that it execut...ovac (Dalian) Vaccine,Technology Co., Ltd. (Sinova...and commercialize human-use vaccines. Sinovac will...ping and commercializing world-class vaccines; the...
(Date:11/25/2009)... DIEGO, Nov. 25 Ardea Bi...hat Barry D. Quart, Pharm.D., president and chief ...ay 21st Annual Health Care Conference. , ,Present...Annual Health Care Conference,Date: Tuesday, ...,Location: The New York Palace Hotel, New York, N...
Breaking Biology Technology:Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 4Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...nference Call Tomorrow (Tuesday) at 8:30 am EDT to... Valley Cottage, NEW YORK, September 10 XTL,Biop...E: XTL) today announced,the initiation of a Phase ... norepinephrine reuptake inhibitor (SNRI) - for th...ine is being developed for the treatment of diabet...
...ltern, a leading global research,organization, is ...,Chiltern,s Country Manager for the Czech Republic...e year award. The award ceremony was held in,Londo...om amongst his peers by a panel of judges who,revi...ccessful conclusion,of clinical trials. The judgin...
Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
Other Biology Technology:XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year 2
(Date:11/25/2009)...ientists at the California Institute of Technology...emotion-like behavior in the fruit fly, Drosophil...relevant to the relationship between the neurotran...ty disorder (ADHD), are described in the December ... brain contains only about 20,000 neurons and has...
(Date:11/25/2009)...BER 25, 2009 Soil is the linchpin of the environm...meet. Despite that, many students see soil as "jus... Soil science educators are challenged with the ta...e critical importance of soil in the environment. ...arth science teachers at University of Nebraska-Li...
(Date:11/24/2009)... Institute (LRI) today named 12 new grant recipien...cognize innovative work across a broad spectrum of...ivity, novelty, and potential to drive scientific ...he complex disease of systemic lupus. , The 2009...rchers across the nation and include interdiscipli...
Breaking Biology News(10 mins):Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4It's not just dirt! 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3PEAK Surgical Announces Results of First PRECISE Studies at American College of Surgeons Clinical Congress 5492 1PEAK Surgical Announces Results of First PRECISE Studies at American College of Surgeons Clinical Congress 5492 2PEAK Surgical Announces Results of First PRECISE Studies at American College of Surgeons Clinical Congress 5492 3Inc Magazine Unveils 28th Annual List of Americas Fastest Growing Private Companies the Inc 500 59482 1Inc Magazine Unveils 28th Annual List of Americas Fastest Growing Private Companies the Inc 500 59482 2IDEXX Laboratories to Release 2009 Third Quarter Financial Results 14472 1
... Society for Microbiology (ASM) Eli Lilly and Comp... Newman, Wilson Professor of Biology and Geobiolog...rd recognizes fundamental research of unusual meri...n the threshold of his or her career. , Dr. Newma...ed the field of geomicrobiology. Her seminal resea...
... Society for Microbiology (ASM) William A. Hinton ...ro Casadevall, Chair, Department of Microbiology a..., Yeshiva University, New York. This award recogni... research training of underrepresented minorities ...emplary training and mentoring to a significant nu...
...ociety for Microbiology (ASM) Merck Irving S. Siga...rrell, Assistant Professor, Department of Microbio...ersity of the Health Sciences (USUHS), Bethesda, M... the Merck Irving S. Sigal Memorial Award is prese...ental in the early discovery of therapies to treat...
Other Biology News:American Society for Microbiology honors Dianne K. Newman 2American Society for Microbiology honors Arturo Casadevall 2
Goat Anti-Mouse IGSF4 Polyclonal Antibody, Unconjugated from R&D Systems
Rat Anti-Mouse Activin RIB / ALK-4 Monoclonal Antibody, Unconjugated, Clone 207304 from R&D Systems
Normal Human Serum from 3H Biomedical AB
...s for SYBR Green, TaqMan, LNA spiked TaqMan, Methy...ghly specific primers are designed by avoiding cro...BLAST search results. Primer efficiency is enhance...fied by connecting to the Mfold server. Beacon Des...
Biology Products: